PC or PCV, that is the question

Primary anaplastic oligodendroglial tumors treated with procarbazine and CCNU with and without vincristine

Courtney Webre, Nicole A Shonka, Lynette M Smith, Diane Liu, John De Groot

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: While procarbazine with 1-(2- chloroethyl)-3-cyclohexyl-1-nitrosourea (PC) added to vincristine (PCV) was proven beneficial in the treatment of co-deleted anaplastic oligodendroglioma (AO), the question of whether PC alone is sufficient is important, as vincristine adds toxicity with uncertain benefit. This retrospective study provides a comparison of PC and PCV. Patients and Methods: Patients diagnosed with AO treated at the M.D. Anderson Cancer Center from June 1, 1993 to October 13, 2009 were selected from the database and were eligible if diagnosed with a primary AO and treated with either PC or PCV at some point. Ninety-seven patients were treated with such chemotherapy before first progression. Results: Initial treatment included radiation and chemotherapy (81.4%) or chemotherapy alone (18.6%). Twenty-one patients (21.6%) received PC during primary treatment, while 76 patients (78.4%) received PCV. Eleven patients reported neurotoxicity in the PCV arm vs. none in the PC arm. Out of the 97 patients, 45 were alive at last contact, with a median followup of 9.9 years. The median overall survival was 6.5 years (95% confidence interval=4.8-16.7 years), while the median progression-free survival was 2.9 years (95% confidence interval=2.0-6.3 years); these differences were not significant (p=0.61 and p=0.28, respectively). Conclusion: Initial therapy with PC achieved comparable results to those of PCV with a median follow-up of 9.9 years. Neurotoxicity was more frequent with vincristine. Although selecting only for patients with AO, rather than those with mixed histology, increased the likelihood of selecting for patients with tumors with co-deletions, further studies with correlative co-deletion status are required.

Original languageEnglish (US)
Pages (from-to)5467-5472
Number of pages6
JournalAnticancer Research
Volume35
Issue number10
StatePublished - Oct 1 2015

Fingerprint

Lomustine
Procarbazine
Vincristine
Oligodendroglioma
Neoplasms
Drug Therapy
Confidence Intervals
Therapeutics
Disease-Free Survival
Histology
Retrospective Studies
Databases
Radiation

Keywords

  • Anaplastic oligoastrocytoma
  • Anaplastic oligodendroglial tumor
  • Anaplastic oligodendroglioma
  • Chemotherapy
  • PCV

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

PC or PCV, that is the question : Primary anaplastic oligodendroglial tumors treated with procarbazine and CCNU with and without vincristine. / Webre, Courtney; Shonka, Nicole A; Smith, Lynette M; Liu, Diane; De Groot, John.

In: Anticancer Research, Vol. 35, No. 10, 01.10.2015, p. 5467-5472.

Research output: Contribution to journalArticle

@article{64be88f77b63461e83ee710f041faabc,
title = "PC or PCV, that is the question: Primary anaplastic oligodendroglial tumors treated with procarbazine and CCNU with and without vincristine",
abstract = "Background: While procarbazine with 1-(2- chloroethyl)-3-cyclohexyl-1-nitrosourea (PC) added to vincristine (PCV) was proven beneficial in the treatment of co-deleted anaplastic oligodendroglioma (AO), the question of whether PC alone is sufficient is important, as vincristine adds toxicity with uncertain benefit. This retrospective study provides a comparison of PC and PCV. Patients and Methods: Patients diagnosed with AO treated at the M.D. Anderson Cancer Center from June 1, 1993 to October 13, 2009 were selected from the database and were eligible if diagnosed with a primary AO and treated with either PC or PCV at some point. Ninety-seven patients were treated with such chemotherapy before first progression. Results: Initial treatment included radiation and chemotherapy (81.4{\%}) or chemotherapy alone (18.6{\%}). Twenty-one patients (21.6{\%}) received PC during primary treatment, while 76 patients (78.4{\%}) received PCV. Eleven patients reported neurotoxicity in the PCV arm vs. none in the PC arm. Out of the 97 patients, 45 were alive at last contact, with a median followup of 9.9 years. The median overall survival was 6.5 years (95{\%} confidence interval=4.8-16.7 years), while the median progression-free survival was 2.9 years (95{\%} confidence interval=2.0-6.3 years); these differences were not significant (p=0.61 and p=0.28, respectively). Conclusion: Initial therapy with PC achieved comparable results to those of PCV with a median follow-up of 9.9 years. Neurotoxicity was more frequent with vincristine. Although selecting only for patients with AO, rather than those with mixed histology, increased the likelihood of selecting for patients with tumors with co-deletions, further studies with correlative co-deletion status are required.",
keywords = "Anaplastic oligoastrocytoma, Anaplastic oligodendroglial tumor, Anaplastic oligodendroglioma, Chemotherapy, PCV",
author = "Courtney Webre and Shonka, {Nicole A} and Smith, {Lynette M} and Diane Liu and {De Groot}, John",
year = "2015",
month = "10",
day = "1",
language = "English (US)",
volume = "35",
pages = "5467--5472",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "10",

}

TY - JOUR

T1 - PC or PCV, that is the question

T2 - Primary anaplastic oligodendroglial tumors treated with procarbazine and CCNU with and without vincristine

AU - Webre, Courtney

AU - Shonka, Nicole A

AU - Smith, Lynette M

AU - Liu, Diane

AU - De Groot, John

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Background: While procarbazine with 1-(2- chloroethyl)-3-cyclohexyl-1-nitrosourea (PC) added to vincristine (PCV) was proven beneficial in the treatment of co-deleted anaplastic oligodendroglioma (AO), the question of whether PC alone is sufficient is important, as vincristine adds toxicity with uncertain benefit. This retrospective study provides a comparison of PC and PCV. Patients and Methods: Patients diagnosed with AO treated at the M.D. Anderson Cancer Center from June 1, 1993 to October 13, 2009 were selected from the database and were eligible if diagnosed with a primary AO and treated with either PC or PCV at some point. Ninety-seven patients were treated with such chemotherapy before first progression. Results: Initial treatment included radiation and chemotherapy (81.4%) or chemotherapy alone (18.6%). Twenty-one patients (21.6%) received PC during primary treatment, while 76 patients (78.4%) received PCV. Eleven patients reported neurotoxicity in the PCV arm vs. none in the PC arm. Out of the 97 patients, 45 were alive at last contact, with a median followup of 9.9 years. The median overall survival was 6.5 years (95% confidence interval=4.8-16.7 years), while the median progression-free survival was 2.9 years (95% confidence interval=2.0-6.3 years); these differences were not significant (p=0.61 and p=0.28, respectively). Conclusion: Initial therapy with PC achieved comparable results to those of PCV with a median follow-up of 9.9 years. Neurotoxicity was more frequent with vincristine. Although selecting only for patients with AO, rather than those with mixed histology, increased the likelihood of selecting for patients with tumors with co-deletions, further studies with correlative co-deletion status are required.

AB - Background: While procarbazine with 1-(2- chloroethyl)-3-cyclohexyl-1-nitrosourea (PC) added to vincristine (PCV) was proven beneficial in the treatment of co-deleted anaplastic oligodendroglioma (AO), the question of whether PC alone is sufficient is important, as vincristine adds toxicity with uncertain benefit. This retrospective study provides a comparison of PC and PCV. Patients and Methods: Patients diagnosed with AO treated at the M.D. Anderson Cancer Center from June 1, 1993 to October 13, 2009 were selected from the database and were eligible if diagnosed with a primary AO and treated with either PC or PCV at some point. Ninety-seven patients were treated with such chemotherapy before first progression. Results: Initial treatment included radiation and chemotherapy (81.4%) or chemotherapy alone (18.6%). Twenty-one patients (21.6%) received PC during primary treatment, while 76 patients (78.4%) received PCV. Eleven patients reported neurotoxicity in the PCV arm vs. none in the PC arm. Out of the 97 patients, 45 were alive at last contact, with a median followup of 9.9 years. The median overall survival was 6.5 years (95% confidence interval=4.8-16.7 years), while the median progression-free survival was 2.9 years (95% confidence interval=2.0-6.3 years); these differences were not significant (p=0.61 and p=0.28, respectively). Conclusion: Initial therapy with PC achieved comparable results to those of PCV with a median follow-up of 9.9 years. Neurotoxicity was more frequent with vincristine. Although selecting only for patients with AO, rather than those with mixed histology, increased the likelihood of selecting for patients with tumors with co-deletions, further studies with correlative co-deletion status are required.

KW - Anaplastic oligoastrocytoma

KW - Anaplastic oligodendroglial tumor

KW - Anaplastic oligodendroglioma

KW - Chemotherapy

KW - PCV

UR - http://www.scopus.com/inward/record.url?scp=84942761707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942761707&partnerID=8YFLogxK

M3 - Article

VL - 35

SP - 5467

EP - 5472

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 10

ER -